# Dennis X. Hu

> Dennis X. Hu is the founder and CEO of Drug Hunter, a subscription knowledge platform that distills the science behind new medicines for more than 200 R&D institutions, including most of the world's top pharma and biotech companies. A medicinal chemist by training, he led small-molecule teams at Genentech and the biotech RAPT Therapeutics (where he helped invent the Phase II oncology candidate tivumecirnon) before turning a side project into a fully remote company of 20+ employees that reaches millions of searches a year and runs entirely on subscription revenue.

- **Role:** Founder & CEO at Drug Hunter
- **Organizations:** Drug Hunter, Genentech, RAPT Therapeutics (FLX Bio)
- **Nationality:** American
- **Education:** PhD, Chemistry, Stanford University, MPhil by Research (Churchill Scholarship), University of Cambridge, Dual BA/MS (Goldwater Scholar), Northwestern University
- **Known for:** Founded and scaled Drug Hunter to serve 200+ R&D institutions including most top global pharma companies, Grew the platform to ~20,000 newsletter subscribers, 50,000+ LinkedIn followers, and 6M+ annual searches, Contributed to the invention of tivumecirnon (Phase II oncology / cancer immunotherapy)

## Career timeline

- **early career** — Medicinal chemist and project team leader at FLX Bio / RAPT Therapeutics; contributed to the invention of tivumecirnon, a Phase II oncology candidate for cancer immunotherapy
- **later** — Small molecule team leader at Genentech
- **2018** — Started Drug Hunter out of frustration with how fragmented and obscure the science behind new drugs had become
- **2022** — Went full-time on building Drug Hunter
- **2023** — Launched Drug Hunter's commercial subscription plan; grew to ~200 institutional customers
- **2025** — Held first full-team in-person gathering in Oregon; crossed 20 full-time US employees
- **2026** — Drug Hunter enters its eighth year, cash-flow positive with 100% of revenue from subscriptions

## Achievements

- Founded and scaled Drug Hunter to serve 200+ R&D institutions including most top global pharma companies
- Grew the platform to ~20,000 newsletter subscribers, 50,000+ LinkedIn followers, and 6M+ annual searches
- Contributed to the invention of tivumecirnon (Phase II oncology / cancer immunotherapy)
- Churchill Scholar (Cambridge) and Goldwater Scholar (Northwestern)
- Built a fully remote company of 10+ full-time PhDs that is cash-flow positive on subscriptions alone

## Latest updates

- **2026-01** — Drug Hunter enters Year 8: cash-flow positive, 100% subscription-funded, 20+ full-time US employees, and appearing in over 6 million searches a year.
- **2025-09** — Company associated with a recent seed-stage funding milestone per public records.

## Links

- Website: https://drughunter.com
- LinkedIn: https://www.linkedin.com/in/dennisxhu
- Twitter/X: https://x.com/denniswhom
- YouTube: https://www.youtube.com/@drughunter
- Facebook: https://www.facebook.com/drughunterofficial/

---

Profile page: https://yespress.io/dennis-hu
Published by YesPress — https://yespress.io
Last updated: 2026-06-24